Oxford Biomedica Management
Management criteria checks 2/4
Oxford Biomedica's CEO is Frank Mathias, appointed in Mar 2023, has a tenure of 1.75 years. total yearly compensation is £520.00K, comprised of 88.1% salary and 11.9% bonuses, including company stock and options. directly owns 0.019% of the company’s shares, worth £85.31K. The average tenure of the management team and the board of directors is 1.3 years and 3.8 years respectively.
Key information
Frank Mathias
Chief executive officer
UK£520.0k
Total compensation
| CEO salary percentage | 88.1% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.02% |
| Management average tenure | 1.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?
Oct 19
Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%
Aug 23Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 15Is Oxford Biomedica (LON:OXB) Using Too Much Debt?
Oct 06Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings
May 02We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn
Jun 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£142m |
| Mar 31 2024 | n/a | n/a | -UK£150m |
| Dec 31 2023 | UK£520k | UK£458k | -UK£157m |
Compensation vs Market: Frank's total compensation ($USD654.44K) is below average for companies of similar size in the UK market ($USD965.92K).
Compensation vs Earnings: Insufficient data to compare Frank's compensation with company performance.
CEO
Frank Mathias (62 yo)
1.8yrs
Tenure
UK£520,000
Compensation
Dr. Frank Mathias is Chief Executive Officer and Director of Oxford Biomedica plc from March 27, 2023. Dr. Mathias was the Chief Executive Officer of Rentschler Biopharma SE from April 2016 until March 202...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | UK£520.00k | 0.019% £ 84.9k | |
| CFO & Director | less than a year | no data | no data | |
| Chief Operating Officer | 1.2yrs | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| General Counsel & Company Secretary | 5.6yrs | no data | no data | |
| Chief People Officer | 2.7yrs | no data | no data | |
| Chief Innovation Officer | less than a year | no data | no data | |
| Head of Intellectual Property and Contracts | no data | no data | no data | |
| Chief Business Officer | 2.1yrs | no data | no data | |
| Site Head of UK Operations | 1.4yrs | no data | no data | |
| Site Head & GM of France Operations | less than a year | no data | no data | |
| Chief of Staff | 1.1yrs | no data | no data |
1.3yrs
Average Tenure
51yo
Average Age
Experienced Management: OXB's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | UK£520.00k | 0.019% £ 84.9k | |
| CFO & Director | less than a year | no data | no data | |
| Non-Executive Chair | 4.5yrs | UK£225.00k | 0.35% £ 1.6m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 1.6yrs | UK£87.00k | 0.012% £ 52.8k | |
| Independent Non-Executive Director | 6.8yrs | UK£140.00k | 0.017% £ 77.7k | |
| Senior Independent Director | 3.8yrs | UK£73.00k | 0.00094% £ 4.2k | |
| Independent Vice Chair | 8.5yrs | UK£85.00k | 0.010% £ 46.1k | |
| Non-Executive Director | 5.5yrs | no data | no data | |
| Independent Non-Executive Director | 2.7yrs | UK£65.00k | 0.0087% £ 38.9k |
3.8yrs
Average Tenure
62yo
Average Age
Experienced Board: OXB's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 19:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oxford Biomedica plc is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rick Bienkowski | Cantor Fitzgerald & Co. |
| Susie Jana | Edison Investment Research |
| Jens Lindqvist | Investec Bank plc (UK) |